Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmuneRegen BioSciences, a wholly owned subsidiary of IR Biosciences, has signed a collaboration and research agreement with the Department of Tumor Immunology of the Radboud University Nijmegen Medical Centre (RUMC), in the Netherlands to commence studies utilising ImmuneRegen's Homspera.
Subscribe to our email newsletter
As per the agreement, cancer vaccine experts at RUMC are expected to perform exploratory studies on Homspera relating to its adjuvant and immunomodulatory properties for potential application in experimental cancer vaccines and immunotherapy for cancer.
ImmuneRegen BioSciences said that Homspera has been shown to be effective in enhancing the efficacy of a novel cancer vaccine in an experimental melanoma model, and previous studies have demonstrated efficacy in enhancing immune responses to infectious disease vaccines, such as influenza. The studies to be performed at RUMC are designed to expand on that research, and further define the mechanisms that make Homspera an effective vaccine adjuvant.
Hal Siegel, chief scientific officer of ImmuneRegen, said: “We are pleased that Adema and his team are interested in evaluating the impact of Homspera in their cancer vaccine models, and hope this is the beginning of a long and fruitful relationship that takes our compound into a number of vaccine adjuvant, and perhaps other, studies.”